Refile: Canada's COSCIENS Biopharma Q2 net loss narrows on higher sales

COSCIENS Biopharma

11/08/2026 22:40

Corrects third Overview bullet to clarify developments ocurred after Q2 ended

Overview
Canada natural ingredients developer's Q2 revenue rose yr/yr, driven by higher sales volumes
Q2 net loss narrowed, reflecting improved gross margins and reduced operating expenses
Subsequent to quarter-end, COSCIENS completed share reorganization, suspending SEC reporting obligations to reduce costs

Outlook
Company expects significant annualized cost-savings from suspension of SEC reporting obligations
COSCIENS says focus is to support Ceapro's growth objectives and explore opportunities for greater scale

Result Drivers
HIGHER SALES VOLUMES - Co said increased sales volumes contributed to higher revenue and improved gross margins in Q2
LOWER OPERATING EXPENSES - Co attributed reduced net loss to lower selling, general and administrative expenses and decreased research and development costs
DISCONTINUED OPERATIONS - Co said reduction of losses from discontinued German subsidiary contributed to improved results

Company press release: ID:nGNX7hzhPx

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$200,000
 
Q2 Operating Expenses
 
$1.30 mln
 

Reuters Recommended Reads
Aug 11 - Canada's Cipher Pharma Q2 revenue falls on lower Natroba sales amid reduced Medicaid coverage
Aug 10 - Canada's Medexus Q1 revenue beats on GRAFAPEX strength
Aug 11 - CK Life Sciences H1 loss narrows on lower R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)